Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis
Clin. transl. oncol. (Print)
; 20(11): 1422-1429, nov. 2018. tab, graf
Article
in English
| IBECS
| ID: ibc-173733
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Purpose:
After surgical resection, an ample prognosis variability among stages is observed. Multiple prognostic factors are individually studied and some CRC classifiers have been proposed. Not one have been implemented into clinical practice. Methods/patients We classified 105 patients with resected CRC (stage I-III) into five molecular subtypes using BRAFV600E and RAS (KRAS; NRAS) status, and the expression of DNA mismatch repair (MMR) proteins (MLH1 and MSH2). Clinicopathological features and DFS) of distincts groups were evaluated. Results andconclusions:
RAS and BRAFV600E mutations were detected in 43.8 and 11.4% of patients, respectively. 19% of tumours had lack of expression of any MMR proteins reflecting a system deficiency (dMMR). Patients with any RAS mutation had lower DFS that patients with RAS wild type (wt) (40.23 vs 45.26 months; p value = 0.035). Of a total of five molecular subtypes, three were MMR proficient (pMMR) RAS mutated (39%), BRAFV600E mutated (6.7%) and RAS/BRAFV600E wt (35.2%); and two were dMMR BRAFV600E mutated (4.8%) and BRAFV600E wt (14.3%). Left side tumours were more frequently observed in pMMR/RAS and BRAFV600E wt subtype, and right side tumours in dMMR subtypes. Among the three pMMR subtypes, a benefit survival was observed for patients without any mutation in BRAFv600E or RAS oncogenes (median of DFS = 45.5 vs 40.98 months in RAS mutated group; p = 0.084 and vs 34.13 in BRAFv600E mutated group; p = 0.031). Molecular classification using these biomarkers can be useful to identify groups with differences in prognosisRESUMEN
No disponible
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Colorectal Neoplasms
/
Biomarkers, Tumor
/
Molecular Diagnostic Techniques
Type of study:
Diagnostic study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2018
Document type:
Article
Institution/Affiliation country:
Fundación Investigación Hospital General Universitario de Valencia/Spain
/
Hospital Arnau de Vilanova/Spain
/
Hospital de Requena/Spain
/
Hospital de Sagunto/Spain
/
Universitat Politècnica de València/Spain